Chemotherapy options for patients suffering from heavily pretreated metastatic breast cancer

Future Oncology

Volumn 11, Issue 12, 2015, Pages 1775-1789

  Jerusalem, Guy ^a   Rorive, Andrée ^a   Collignon, Joëlle ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

capecitabine; chemotherapy; eribulin; etirinotecan pegol; gemcitabine; irinotecan; ixabepilone; metastatic breast cancer; randomized trial; vinorelbine

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL PRODUCT; CAPECITABINE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; ERIBULIN; ETIRINOTECAN PEGOL; FIRTECAN; FLUOROURACIL; GEMCITABINE; IRINOTECAN; IXABEPILONE; NAVELBINE; PACLITAXEL; SUNITINIB; TAXANE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLEEDING; BRAIN METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HAZARD RATIO; HUMAN; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SENSORY NEUROPATHY; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER; BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; PATHOLOGY; SECONDARY;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS;

EID: 84931330928     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.80     Document Type: Review

References (37)

1. El Saghir N, Tfayli A, Hatoum HA, Nachef Z, Dinh P, Awada A. Treatment of metastatic breast cancer: state-of-the-art, subtypes and perspectives. Crit. Rev. Oncol. Hematol. 80, 433-449 (2011).
2. Pagani O, Senkus E, Wood W et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J. Natl Cancer Inst. 102(7), 456-463 (2010).
3. Moreno-Aspitia A, Perez EA. Treatment options for breast cancer resistant to Anthracycline and Taxane. Mayo Clin. Proc. 84(6), 533-545 (2009).
4. Hortobagyi GN. Treatment of breast cancer. N. Engl. J. Med. 339(14), 974-984 (1998).
5. Valero V, Hortobagyi GN. Are Anthracycline-Taxane regimens the new standard of care in the treatment of metastatic breast cancer? J. Clin. Oncol. 21(6), 959-962 (2003).
6. Bernard-Marty C, Cardoso F, Piccart MJ. Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist 9, 617-632 (2004).
7. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005).
8. De Laurentiis M, Cancello G, D'Agostino D et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J. Clin. Oncol. 26(1), 44-53 (2008).
9. Blum JL, Jones SE, Buzdar AU et al. Multicenter Phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J. Clin. Oncol. 17(2), 485-493 (1999).
10. Blum JL, Dieras V, Lo Russo PM et al. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92(7), 1759-1768 (2001).
11. Reichardt P, Von Minckwitz G, Thuss-Patience PC et al. Multicenter Phase II study of oral capecitabine (Xeloda®) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann. Oncol. 14(8), 1227-1233 (2003).
12. Fumoleau P, Largillier R, Clippe C et al. Multicentre, Phase II study evaluating capecitabine monotherapy in patients with anthracycline-and taxane-pretreated metastatic breast cancer. Eur. J. Cancer 40(4), 536-542 (2004).
13. Largillier R, Fumoleau P, Clippe C et al. Capecitabine (X) monotherapy after anthracycline and taxane failure in metastatic breast cancer (MBC): long-term survival data. Ann. Oncol. 17(Suppl. 9), ix74 (2006).
14. Miller KD, Chap LI, Holmes FA et al. Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. 23(4), 792-799 (2005).
15. Crown JP, Dieras V, Staroslawska E et al. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J. Clin. Oncol. 31(23), 2870-2878 (2013).
16. Barrios CH, Liu MC, Lee SC et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res. Treat. 121(1), 121-131 (2010).
17. Toi M, Saeki T, Aogi K et al. Late Phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes. Jpn. J. Clin. Oncol. 35(6), 310-315 (2005).
18. Seo HY, Lee HJ, Woo OH, Park KH, Woo SU, Yang DS et al. Phase II study of vinorelbine monotherapy in anthracycline and taxane pre-treated metastatic breast cancer. Invest New Drugs 29(2), 360-365 (2011).
19. Martin M, Ruiz A, Munoz M et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the Phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol. 8(3), 219-225 (2007).
20. Pallis AG, Boukovinas I, Ardavanis A et al. A multicenter randomized Phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracyclineand taxane-pretreated women with metastatic breast cancer. Ann. Oncol. 23(5), 1164-1169 (2012).
21. Bollag DM, McQueney PA, Zhu J et al. Epothilones, a new class of microtubulestabilizing agents with a taxol-like mechanism of action. Cancer Res. 55(11), 2325-2333 (1995).
22. Perez EA, Lerzo G, Pivot X et al. Efficacy and safety of ixabepilone (BMS-247550) in a Phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J. Clin. Oncol. 25(23), 3407-3414 (2007).
23. Thomas ES, Gomez HL, Li RK et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J. Clin. Oncol. 25(33), 5210-5217 (2007).
24. Sparano JA, Vrdoljak E, Rixe O et al. Randomized Phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 28(20), 3256-3263 (2010).
25. Cortes J, O'Shaughnessy J, Loesch D et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a Phase 3 open-label randomised study. Lancet 377(9769), 914-923 (2011).
26. Kaufman PA, Awada A, Twelves C et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 33(6), 594-601 (2015).
27. Perez EA, Hillman DW, Mailliard JA et al. Randomized Phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J. Clin. Oncol. 22(14), 2849-2855 (2004).
28. Awada A, Garcia AA, Chan S, Jerusalem GH, Coleman RE, Huizing MT et al. Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised Phase 2 study. Lancet Oncol. 14(12), 1216-1225 (2013).
29. Pommier Y, Tanizawa A, Kohn KW. Mechanisms of topoisomerase I inhibition by anticancer drugs. Adv. Pharmacol. 29B, 73-92 (1994).
30. de Forni M, Bugat R, Chabot GG et al. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res. 54(16), 4347-4354 (1994).
31. Rothenberg ML, Kuhn JG, Burris HA, III, Nelson J, Eckardt JR, Tristan-Morales M et al. Phase I and pharmacokinetic trial of weekly CPT-11. J. Clin. Oncol. 11(11), 2194-2204 (1993).
32. Rowinsky EK, Grochow LB, Ettinger DS et al. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every weeks. Cancer Res. 54(2), 427-436 (1994).
33. Jameson GS, Hamm JT, Weiss GJ, Alemany C, Anthony S, Basche M et al. A multicenter, Phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors. Clin. Cancer Res. 19, 268-278 (2013).
34. Hoch U, Staschen CM, Johnson RK, Eldon MA. Nonclinical pharmacokinetics and activity of Etirinotecan Pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models, Cancer Chemother. Pharmacol. 74, 1125-1137 (2014).
35. Eldon MA, Staschen CM, Viegas T, Bentley M. NKTR-102, a novel PEGylated-irinotecan conjugate, results in sustained tumor growth inhibition in mouse models of human colorectal and lung tumors that is associated with increased and sustained tumor SN-38 exposure. Proc. Am. Assoc. Cancer Res. 306, Abstract C157 (2007).
36. US National Institutes of Health. http://clinicaltrials.gov
37. Press release: Nektar Therapeutics, San Francisco, CA, USA, 15 March 2015. http://ir.nektar.com